What is a stock summary page? Click here for an overview.
Business Description
Acrivon Therapeutics Inc
NAICS : 541713
SIC : 2833
ISIN : US0048901096
Description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.92 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -130.9 | |||||
| 3-Year EPS without NRI Growth Rate | -88.1 | |||||
| 3-Year FCF Growth Rate | -108.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.04 | |||||
| 9-Day RSI | 15.55 | |||||
| 14-Day RSI | 21.42 | |||||
| 3-1 Month Momentum % | -11.79 | |||||
| 6-1 Month Momentum % | -24.14 | |||||
| 12-1 Month Momentum % | -25.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.5 | |||||
| Shareholder Yield % | 0.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -49.18 | |||||
| ROA % | -44.72 | |||||
| ROIC % | -168.79 | |||||
| 3-Year ROIIC % | -513.45 | |||||
| ROC (Joel Greenblatt) % | -1185.53 | |||||
| ROCE % | -52.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.3 | |||||
| Price-to-Tangible-Book | 0.3 | |||||
| EV-to-EBIT | 1.27 | |||||
| EV-to-Forward-EBIT | -0.03 | |||||
| EV-to-EBITDA | 1.28 | |||||
| EV-to-FCF | 1.66 | |||||
| Price-to-Net-Current-Asset-Value | 2.63 | |||||
| Price-to-Net-Cash | 2.63 | |||||
| Earnings Yield (Greenblatt) % | 78.74 | |||||
| FCF Yield % | -130.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACRV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acrivon Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.44 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 97.46 | ||
| 14-Day RSI | 21.42 | ||
| 14-Day ATR ($) | 0.533132 | ||
| 20-Day SMA ($) | 4.789 | ||
| 12-1 Month Momentum % | -25.73 | ||
| 52-Week Range ($) | 1.56 - 11.9 | ||
| Shares Outstanding (Mil) | 31.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acrivon Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acrivon Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Acrivon Therapeutics Inc Frequently Asked Questions
What is Acrivon Therapeutics Inc(ACRV)'s stock price today?
The current price of ACRV is $1.68. The 52 week high of ACRV is $11.90 and 52 week low is $1.56.
When is next earnings date of Acrivon Therapeutics Inc(ACRV)?
The next earnings date of Acrivon Therapeutics Inc(ACRV) is 2025-05-14 Est..
Does Acrivon Therapeutics Inc(ACRV) pay dividends? If so, how much?
Acrivon Therapeutics Inc(ACRV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers